SOPH Stock Recent News

SOPH LATEST HEADLINES

SOPH Stock News Image - seekingalpha.com

SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.

seekingalpha.com 2025 May 10
SOPH Stock News Image - zacks.com

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.

zacks.com 2025 May 06
SOPH Stock News Image - prnewswire.com

BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter  2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024

prnewswire.com 2025 May 06
SOPH Stock News Image - prnewswire.com

BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.

prnewswire.com 2025 Apr 28
SOPH Stock News Image - prnewswire.com

BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

prnewswire.com 2025 Apr 22
SOPH Stock News Image - prnewswire.com

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.

prnewswire.com 2025 Apr 08
SOPH Stock News Image - zacks.com

SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com 2025 Mar 21
SOPH Stock News Image - prnewswire.com

BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.

prnewswire.com 2025 Mar 18
SOPH Stock News Image - seekingalpha.com

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today.

seekingalpha.com 2025 Mar 04
SOPH Stock News Image - zacks.com

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.

zacks.com 2025 Mar 04
10 of 31